Category

News
For this week’s Article of the Week we have chosen a review article published in the British Journal of Haematology co-authored by MSAG member Dr Andrew Zannettino. This review focuses on the genetic changes associated with the evolution of Monoclonal Gammopathy of Unknown Significance (MGUS) and the progression to Multiple Myeloma (MM). Cutting edge genomics...
Continue Reading
For this week’s Article of the Week we have chosen an article which is particularly relevant to the results of the recent VCAT study which is currently being prepared for publication. It features a study  recently published in the British Journal of Haematology comparing the use of bortezomib consolidation therapy with observation only in patients...
Continue Reading
For this week’s Article of the Week relates to a presentation made by Petere Croucher on the osteocyte-specific protein sclerostin at the most recent MSAG meeting. It is an article published this month in Blood on the use of sclerostin to increase bone mass and reduce the incidence of fractures in multiple myeloma. Inhibiting the osteocyte-specific protein sclerostin increases...
Continue Reading
García-Guerrero et al described their laboratory study where myeloma cells from 12 patients were treated with titrated doses of panobinostat (0, 10 and 25nM). In order to assess CD38 expression, the authors used flow cytometry after exposure to panobinostat. The authors then went on to assess whether an increase in CD38 expression caused by panobinostat...
Continue Reading
A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma’ is a study intended to assess the safety, efficacy and pharmacokinetics of the anti-CD38 monoclonal antibody isatuximab given in 2 different regimens in combination with lenalidomide and dexamethasone. The study included 57 patients in total with a confirmed diagnosis of multiple myeloma...
Continue Reading
This week’s Article of the Week is a study that was recently published in the British Journal of Haematology on the role of serum IgM levels as a predictor of symptomatic hyperviscosity in Waldenström’s macroglobulinaemia (WM). Gustine et al’s paper ‘Serum IgM level as predictor of symptomatic hyper viscosity in patients with Waldenström macroglobulinaemia’ is based on the premise that...
Continue Reading
Multiple Myeloma
About 400 New Zealanders a year are diagnosed with the blood cancer multiple myeloma, and the number is rising. A malignancy of the plasma cell, it led to destruction of the body’s defence mechanisms, and was the second most common blood cancer being treated in this country, after Non-Hodgkin’s lymphoma. Survival with the cancer had...
Continue Reading
This review discusses pre-clinical and clinical studies on the use of monoclonal antibodies in multiple myeloma, including agents which have been shown to have no activity against myeloma cells. It outlines various agents and their specific targets, focusing particularly on those agents with strong evidence in clinical trials. This review highlights the benefits of immunotherapy...
Continue Reading
On November 22,  2016  in Wellington a group of New Zealand based hematology specialists led by Kenneth Romeril launched a new initiative for multiple myeloma patients, Multiplemyeloma.org.nz. Why? All too often when diagnosed with life threatening disease, patients turn to Dr Google to find out all they can. More often than not it’s not local information...
Continue Reading
1 16 17 18

Floor 7, 90 The Terrace
Wellington Central
New Zealand